Prior clinical trials have demonstrated promising efficacy and manageable safety of surufatinib in neuroendocrine tumors (NETs). This real-world study aims to evaluate the clinical efficacy and safety of surufatinib in patients with NETs, providing additional real-world evidence to support clinical application, guide novel therapeutic strategies, and ultimately improve patient outcomes.
Patients with pathologically or cytologically confirmed neuroendocrine tumors;
At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1;
Life expectancy ≥ 12 weeks;
Adequate organ and bone marrow function
Participation in other drug clinical trials with investigational drug treatment within the past 4 weeks;
History of other malignancies within the past 5 years, except for curatively resected basal cell or squamous cell carcinoma of the skin, or cervical carcinoma in situ;
Patients with contraindications to surufatinib (e.g., active bleeding, ulcer, intestinal perforation, intestinal obstruction, medically uncontrolled hypertension, grade III-IV cardiac dysfunction, within 30 days after major surgery, severe hepatic or renal impairment, etc.);
Presence of any disease or condition that affects drug absorption, or inability to take surufatinib orally;
Yefeng
Lead sponsor
The First Affiliated Hospital of Xiamen University
Sponsor institution